TickerTalks
Browse all tickers →
TickerTalks›$ZYBT
ZYZYBT

Zhengye Biotechnology Holding Limited

$ZYBT·$63M·Drug Manufacturers - Specialty & Generic·Healthcare
$1.61-1.2%YTD+13.3%1Y-83.3%
Mentions · last 7 days
38
Price updated 1h ago·X counts updated 12d ago
ZYZYBT
$ZYBTZhengye Biotechnology Holding Limited
$1.61-1.23%38 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $ZYBT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeStalledAI verdict · as of 2026-09-03

The move has stalled — likely just drifts unless something new shows up.

Zhengye Biotechnology -87% TTM but momentum-scan darling — July run cited +850% from $1.20 to $11.40, now back at $1.63 with Nasdaq compliance.

Zhengye Biotechnology is a China-based specialty pharma (drug manufacturers, specialty and generic). Down 87% TTM at $1.63 — stalled after a violent July retail-momentum run that has since faded.

  • The core is unprofitable at scale: Q4 revenue $53.0M, 8% gross margin (very thin for a pharma name), -77% operating margin, Q4 EPS -$0.98. FCF yield 1.5% and ROIC -16.1% show underlying operational stress; there are no forward analyst estimates because analyst coverage is thin at this size.
  • The catalyst mix is a compliance overhang plus retail-momentum echo: Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement (resolves an immediate delisting risk). Comments on Unusual Trading Activity (a required disclosure after the July spike). Prior two Notifications Regarding Minimum Bid Price Deficiency captured the pre-recovery period.
  • The insider signal is empty: no insider prints in the window either way. X chatter is uniformly bullish day-trader momentum content — retail traders claim a call at $1.20 that hit $11.40 for +850%, part of a broader July run for microcap momentum names alongside CPHI ($3 → $19.19), ADVB, STAK, DFNS, STKH. Some holders got stuck in halts (-$27k blowup cited). Momentum-scan chatter groups ZYBT with other 'China's' JLHL, ZCMD, PN.

Breaks stall upward: a commercial-product-launch catalyst plus Nasdaq compliance maintenance. Deepens: another minimum bid price deficiency, or a Chinese ADR delisting proposal from the SEC.

Agrees with X sentimentX is bullish day-trader momentum content — the July $1.20 → $11.40 run was real (+850%), but that momentum has clearly faded and the stock is back to $1.63. The mechanics support the caution: -87% TTM, -77% operating margin, and the pattern of Nasdaq minimum bid price deficiency notifications is a real structural risk. This is a pure retail-momentum name, not a fundamental thesis.

What to watch: Continued Nasdaq minimum bid price compliance, and any commercial-product-launch announcement. Also SEC action on Chinese ADR delisting proposals, and any specific FDA/CFDA regulatory update.

On the calendar: No confirmed next earnings — TBA

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-08-01

ZYBT chatter is uniformly bullish day-trader momentum content. Retail traders claim a call at $1.20 that hit $11.40 for +850% - part of a broader July run for microcap momentum names alongside CPHI ($3 → $19.19, +539%), ADVB ($6.30 → $25.84), STAK, DFNS and STKH. Some holders got stuck in halts (-$27k blowup cited). Momentum-scan chatter groups ZYBT with other 'China's' JLHL, ZCMD, PN.

Read the AI verdict + X sentiment for $ZYBT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese animal vaccine manufacturer supplying swine, poultry, and livestock immunizations domestically and exporting to Southeast Asia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $ZYBT.

Drug Manufacturers - Specialty & Generic · Healthcare

Biosimilar launches are compressing margins on branded specialty drugs; the opportunity is on the generic/biosimilar side where volume gains offset price erosion. Rare disease and oncology are the premium pockets where pricing power remains intact.

What this means for $ZYBT

Neutral — network operator exposure is to subscriber economics and capex cycles, not directly to the industry macro driver.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-36.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-16.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-77.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
32.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
8.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$53.0M—8.3%-77.0%$-0.98$25.8M
Q3 FY25$27.0M—8.3%-77.0%$-0.51$13.3M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+32.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 4.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-2.535-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 253
AI summary

Han Zhenfa, Director and 10%+ owner of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing indirect beneficial ownership of 42,963,748 ordinary shares across three BVI holding entities: 40,000,000 shares via Securingium Holding Limited (held through a family trust of which Han is settlor, beneficiary, and protector), 2,278,752 via Vanguards Skyline Holdings Limited, and 684,996 via VVAX Holdings Limited. This is a material 10%+ owner disclosure revealing a concentrated, multi-entity controlling stake typical of a founder/principal investor in a recently listed Chinese biotech.

3New insider — initial holdingsJun 253
AI summary

Cheng Yuhong, Vice General Manager of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. This is a routine SEC Section 16 compliance filing required upon becoming an officer of a reporting company; no ownership position or investment activity is reported.

3New insider — initial holdingsJun 253
AI summary

Song Songlin, Co-Chief Executive Officer of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. Routine Section 16 compliance filing by an executive officer; no ownership position or investment activity reported.

3New insider — initial holdingsJun 253
AI summary

Wang Ping, Chief Financial Officer of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. This is a routine Section 16 compliance filing required upon becoming an officer of a public company; no ownership position or investment activity is reported.

3New insider — initial holdingsJun 253
AI summary

Jiang Ping, Director of Zhengye Biotechnology Holding Ltd (ZYBT), filed an initial Form 3 on June 25, 2026, disclosing no beneficially owned securities. Routine Section 16 compliance filing by a director; no ownership position or investment activity reported.

3New insider — initial holdingsApr 243
3New insider — initial holdingsApr 243
3New insider — initial holdingsMar 183
+ 8 other (4 6-Ks · 3 3s · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirementglobenewswire.com·29d agoZhengye Biotechnology Holding Limited Comments on Unusual Trading Activityglobenewswire.com·45d agoZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyglobenewswire.com·92d agoZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyglobenewswire.com·92d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEVA$EVO$ACB$TAK$INDV$ELAN$AQST$RGC
Voices on X · last 7 days

No standout posts about $ZYBT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport